- Home
- KRG vs BLCO Comparison
KRG vs BLCO Comparison
Compare KRG & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRG
- BLCO
- Stock Information
- Founded
- KRG 1971
- BLCO 1853
- Country
- KRG United States
- BLCO Canada
- Employees
- KRG N/A
- BLCO N/A
- Industry
- KRG Real Estate Investment Trusts
- BLCO Ophthalmic Goods
- Sector
- KRG Real Estate
- BLCO Health Care
- Exchange
- KRG Nasdaq
- BLCO Nasdaq
- Market Cap
- KRG 5.0B
- BLCO 5.2B
- IPO Year
- KRG 2004
- BLCO 2022
- Fundamental
- Price
- KRG $23.13
- BLCO $16.16
- Analyst Decision
- KRG Buy
- BLCO Hold
- Analyst Count
- KRG 8
- BLCO 14
- Target Price
- KRG $25.50
- BLCO $16.69
- AVG Volume (30 Days)
- KRG 1.7M
- BLCO 537.4K
- Earning Date
- KRG 10-29-2025
- BLCO 10-29-2025
- Dividend Yield
- KRG 5.03%
- BLCO N/A
- EPS Growth
- KRG N/A
- BLCO N/A
- EPS
- KRG 0.64
- BLCO N/A
- Revenue
- KRG $856,786,000.00
- BLCO $4,976,000,000.00
- Revenue This Year
- KRG $2.97
- BLCO $8.12
- Revenue Next Year
- KRG $1.74
- BLCO $5.81
- P/E Ratio
- KRG $36.28
- BLCO N/A
- Revenue Growth
- KRG 3.78
- BLCO 6.23
- 52 Week Low
- KRG $18.52
- BLCO $10.45
- 52 Week High
- KRG $28.24
- BLCO $20.71
- Technical
- Relative Strength Index (RSI)
- KRG 61.64
- BLCO 59.04
- Support Level
- KRG $21.89
- BLCO $14.44
- Resistance Level
- KRG $23.25
- BLCO $16.81
- Average True Range (ATR)
- KRG 0.44
- BLCO 0.60
- MACD
- KRG 0.08
- BLCO 0.02
- Stochastic Oscillator
- KRG 89.71
- BLCO 72.15
About KRG Kite Realty Group Trust
Kite Realty Group Trust specializes in owning, operating, acquiring, developing, and redeveloping high-quality open-air shopping centers and mixed-use assets. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.